BMEA
HEALTHCAREBiomea Fusion Inc
$1.60+0.08 (+5.26%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving BMEA Today?
No stock-specific AI insight has been generated for BMEA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.87$3.08
$1.60
Fundamentals
Market Cap$116M
P/E Ratio—
EPS$-1.18
Dividend Yield—
Dividend / Share—
ROE-1.5%
Profit Margin—
Debt / Equity—
Trading
Volume1.8M
Avg Volume (10D)—
Shares Outstanding72.3M
BMEA News
20 articles- Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific SessionsYahoo Finance·May 5, 2026
- Biomea Fusion Status Update: Experts Discuss Icovamenib’s Promise Ahead of ADA 2026Marketbeat·May 5, 2026
- Biomea Fusion Shares Early Type 1 Diabetes Data as COVALENT-112 Shows C-Peptide Gains with IcovamenibMarketbeat·Apr 28, 2026
- Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib TreatmentYahoo Finance·Apr 27, 2026
- Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care TherapiesGlobeNewswire Inc.·Mar 31, 2026
- Biomea Fusion Details Icovamenib Diabetes Milestones, Teases BMF-650 Obesity ReadoutsMarketbeat·Mar 30, 2026
- Biomea Fusion Teases Q2 Phase 1 Data for Oral GLP-1 BMF-650, Advances Icovamenib in DiabetesMarketbeat·Mar 30, 2026
- Can Biomea Fusion (NASDAQ:BMEA) Afford To Invest In Growth?Yahoo Finance·Mar 27, 2026
- Analysts Sentiment on Biomea Fusion (BMEA) Remains Strong Amid Strong Diabetes Trial ResultsYahoo Finance·Mar 25, 2026
- Biomea Fusion Reports Full Year 2025 Financial Results and Corporate HighlightsYahoo Finance·Mar 24, 2026
- Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026Yahoo Finance·Mar 14, 2026
- Biomea Fusion Details Diabetes, Obesity Pipeline at Citizens Conference, Sees Cash Runway to Q1 2027Marketbeat·Mar 13, 2026
- Biomea Fusion Spotlights Durable Diabetes Data, Oral GLP-1 Weight-Loss Program at Oppenheimer Conf.Marketbeat·Feb 27, 2026
- Biomea Fusion to Participate at Upcoming Investor ConferencesYahoo Finance·Feb 19, 2026
- Biomea Fusion, Inc.'s (NASDAQ:BMEA) largest shareholders are retail investors with 55% ownership, institutions own 38%Yahoo Finance·Jan 24, 2026
- Rodman & Renshaw Initiates Biomea Fusion (BMEA) at Buy with $8 Price TargetYahoo Finance·Jan 19, 2026
- Biomea Fusion Spotlights Diabetes, Obesity Pipeline at JPMorgan Conference, Sets 2026 MilestonesMarketbeat·Jan 15, 2026
- Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 MilestonesYahoo Finance·Jan 12, 2026
- Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare ConferenceYahoo Finance·Dec 17, 2025
- Insider Spends US$99k Buying More Shares In Biomea FusionYahoo Finance·Dec 11, 2025
All 20 articles loaded
Price Data
Open$1.64
Previous Close$1.52
Day High$1.73
Day Low$1.59
52 Week High$3.08
52 Week Low$0.87
52-Week Range
$0.87$3.08
$1.60
Fundamentals
Market Cap$116M
P/E Ratio—
EPS$-1.18
Dividend Yield—
Dividend / Share—
ROE-1.5%
Profit Margin—
Debt / Equity—
Trading
Volume1.8M
Avg Volume (10D)—
Shares Outstanding72.3M
About Biomea Fusion Inc
Biomea Fusion, Inc., a biopharmaceutical company, is focused on the discovery, development and commercialization of irreversible small molecules to treat patients with genetically defined cancers. The company is headquartered in Redwood City, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—